Five-Year Retention of Perampanel and Polytherapy Patterns: 328 Patients From a Single Center in South Korea.

ABSTRACT:

Background and purpose

Perampanel (PER) is an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist used to treat focal and generalized epilepsy. Comprehensive data from real-world settings with long-term follow-ups are still scarce. This study aimed to determine the factors related to PER retention and the polytherapy pattern with PER.

Methods

We reviewed all patients with epilepsy with a history of PER prescription during 2008-2017 and over a follow-up of >3 years. PER usage patterns and associated factors were analyzed.

Results

Among the 2,655 patients in the cohort, 328 (150 females, 178 males) were enrolled. The ages at onset and diagnosis were 21.1±14.7 years and 25.6±16.1 years (mean±standard deviation), respectively. The age at the first visit to our

SUBMITTER: Park KI 

PROVIDER: S-EPMC10329921 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature